http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Sun, 23 Aug 2026 21:54:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Rznomics+Joins+Lilly+Gateway+Labs+in+San+Diego+to+Accelerate+RNA+Therapeutics/26963222.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/kr..sengnam" idsrc="xmltag.org" >SEONGNAM, South Korea</location></span>, <span class="legendSpanClass"><chron>Aug. 23, 2026</chron></span> /PRNewswire/ -- Rznomics Inc.(KOSDAQ: 476830), a biopharmaceutical company specializing in the development of RNA-based gene therapies, announced that it is joining <span>Lilly Gateway Labs</span> (LGL) in <location value="LU/us.ca.sandgo" idsrc="xmltag.org" >San Diego, California</location>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> <img src="https://mmx.prnewswire.com/media/MS1830927/RznomicsLogo.jpg?id=OA2905269" title="Rznomics Inc. logo" alt="Rznomics Inc. logo" /> http://www.streetinsider.com/Press+Releases/Rznomics+Joins+Lilly+Gateway+Labs+in+San+Diego+to+Accelerate+RNA+Therapeutics/26963222.html Sun, 23 Aug 2026 21:54:00 -0400 476830 http://www.streetinsider.com/PRNewswire/Rznomics+Joins+Lilly+Gateway+Labs+in+San+Diego+to+Accelerate+RNA+Therapeutics/26963222.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/kr..sengnam" idsrc="xmltag.org" >SEONGNAM, South Korea</location></span>, <span class="legendSpanClass"><chron>Aug. 23, 2026</chron></span> /PRNewswire/ -- Rznomics Inc.(KOSDAQ: 476830), a biopharmaceutical company specializing in the development of RNA-based gene therapies, announced that it is joining <span>Lilly Gateway Labs</span> (LGL) in <location value="LU/us.ca.sandgo" idsrc="xmltag.org" >San Diego, California</location>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> <img src="https://mmx.prnewswire.com/media/MS1830927/RznomicsLogo.jpg?id=OA2905269" title="Rznomics Inc. logo" alt="Rznomics Inc. logo" /> http://www.streetinsider.com/PRNewswire/Rznomics+Joins+Lilly+Gateway+Labs+in+San+Diego+to+Accelerate+RNA+Therapeutics/26963222.html Sun, 23 Aug 2026 21:54:00 -0400 476830 http://www.streetinsider.com/Press+Releases/Rznomics+Presents+Clinical+Interim+Data+for+RZ-001+in+Recurrent+Glioblastoma+at+ASNO+2026/26643024.html <div class="xn-content"> <ul type="disc"><li><b><span id="spanHghlt96ee">Dr. <person>Chae-Yong Kim</person></span> of <span>Seoul National University Bundang Hospital</span> delivers oral presentation on interim data from 10 enrolled patients</b></li><li><b>A manageable safety profile, with prolonged disease control and tumor recurrence inhibition observed in several patients</b></li></ul><p><span class="legendSpanClass"><location value="LU/kr..sengnam" idsrc="xmltag.org" >SEONGNAM</location> and <location value="LU/kr..seoul" idsrc="xmltag.org" >SEOUL, South Korea</location></span>, <span class="legendSpanClass"><chron>June 15, 2026</chron></span> /PRNewswire/ -- Rznomics Inc., a biopharmaceutical company specializing in the development of RNA-based gene therapies, announced that the Phase 1/2a interim clinical results for 'RZ-001 (Taspitimagene advec)', its RNA editing-based anticancer gene therapy for recurrent glioblastoma (rGBM), were presented on <chron>June 13th</chron> at the <span>Asian Society for Neuro-Oncology</span> http://www.streetinsider.com/Press+Releases/Rznomics+Presents+Clinical+Interim+Data+for+RZ-001+in+Recurrent+Glioblastoma+at+ASNO+2026/26643024.html Mon, 15 Jun 2026 00:00:00 -0400 476830 http://www.streetinsider.com/PRNewswire/Rznomics+Presents+Clinical+Interim+Data+for+RZ-001+in+Recurrent+Glioblastoma+at+ASNO+2026/26643024.html <div class="xn-content"> <ul type="disc"><li><b><span id="spanHghlt96ee">Dr. <person>Chae-Yong Kim</person></span> of <span>Seoul National University Bundang Hospital</span> delivers oral presentation on interim data from 10 enrolled patients</b></li><li><b>A manageable safety profile, with prolonged disease control and tumor recurrence inhibition observed in several patients</b></li></ul><p><span class="legendSpanClass"><location value="LU/kr..sengnam" idsrc="xmltag.org" >SEONGNAM</location> and <location value="LU/kr..seoul" idsrc="xmltag.org" >SEOUL, South Korea</location></span>, <span class="legendSpanClass"><chron>June 15, 2026</chron></span> /PRNewswire/ -- Rznomics Inc., a biopharmaceutical company specializing in the development of RNA-based gene therapies, announced that the Phase 1/2a interim clinical results for 'RZ-001 (Taspitimagene advec)', its RNA editing-based anticancer gene therapy for recurrent glioblastoma (rGBM), were presented on <chron>June 13th</chron> at the <span>Asian Society for Neuro-Oncology</span> http://www.streetinsider.com/PRNewswire/Rznomics+Presents+Clinical+Interim+Data+for+RZ-001+in+Recurrent+Glioblastoma+at+ASNO+2026/26643024.html Mon, 15 Jun 2026 00:00:00 -0400 476830 http://www.streetinsider.com/Press+Releases/Rznomics+Announces+U.S.+FDA+Regenerative+Medicine+Advanced+Therapy+Designation+Granted+to+%27RZ-001%27+for+Hepatocellular+Carcinoma/26456374.html <div class="xn-content"> <p><i>RMAT</i> <i>designation</i> <i>based on promising</i> <i>Phase</i> <i>1b/2a</i> <i>clinical data, including</i> <i>safety profile and preliminary response rates,</i> <i>with trans-splicing ribozyme-based RNA editing</i> <i>platform</i></p><p><span class="legendSpanClass"><location value="LU/kr..seoul" idsrc="xmltag.org" >SEOUL, South Korea</location></span>, <span class="legendSpanClass"><chron>May 8, 2026</chron></span> /PRNewswire/ -- Rznomics a biopharmaceutical company specializing in RNA-based gene therapeutics, announced today that the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food and Drug Administration</span> (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) Designation to RZ-001, its lead investigational candidate for the treatment of hepatocellular carcinoma (HCC).</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Rznomics+Announces+U.S.+FDA+Regenerative+Medicine+Advanced+Therapy+Designation+Granted+to+%27RZ-001%27+for+Hepatocellular+Carcinoma/26456374.html Fri, 08 May 2026 04:17:00 -0400 476830 A.06822034 A.35552990 O.00074346 O.20026344 http://www.streetinsider.com/PRNewswire/Rznomics+Announces+U.S.+FDA+Regenerative+Medicine+Advanced+Therapy+Designation+Granted+to+%27RZ-001%27+for+Hepatocellular+Carcinoma/26456374.html <div class="xn-content"> <p><i>RMAT</i> <i>designation</i> <i>based on promising</i> <i>Phase</i> <i>1b/2a</i> <i>clinical data, including</i> <i>safety profile and preliminary response rates,</i> <i>with trans-splicing ribozyme-based RNA editing</i> <i>platform</i></p><p><span class="legendSpanClass"><location value="LU/kr..seoul" idsrc="xmltag.org" >SEOUL, South Korea</location></span>, <span class="legendSpanClass"><chron>May 8, 2026</chron></span> /PRNewswire/ -- Rznomics a biopharmaceutical company specializing in RNA-based gene therapeutics, announced today that the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food and Drug Administration</span> (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) Designation to RZ-001, its lead investigational candidate for the treatment of hepatocellular carcinoma (HCC).</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/PRNewswire/Rznomics+Announces+U.S.+FDA+Regenerative+Medicine+Advanced+Therapy+Designation+Granted+to+%27RZ-001%27+for+Hepatocellular+Carcinoma/26456374.html Fri, 08 May 2026 04:17:00 -0400 476830 A.06822034 A.35552990 O.00074346 O.20026344 http://www.streetinsider.com/Press+Releases/Rznomics+Announces+U.S.+FDA+Regenerative+Medicine+Advanced+Therapy+Designation+Granted+to+%27RZ-001%27+for+Hepatocellular+Carcinoma/26456374.html <div class="xn-content"> <p><i>RMAT</i> <i>designation</i> <i>based on promising</i> <i>Phase</i> <i>1b/2a</i> <i>clinical data, including</i> <i>safety profile and preliminary response rates,</i> <i>with trans-splicing ribozyme-based RNA editing</i> <i>platform</i></p><p><span class="legendSpanClass"><location value="LU/kr..seoul" idsrc="xmltag.org" >SEOUL, South Korea</location></span>, <span class="legendSpanClass"><chron>May 8, 2026</chron></span> /PRNewswire/ -- Rznomics a biopharmaceutical company specializing in RNA-based gene therapeutics, announced today that the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food and Drug Administration</span> (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) Designation to RZ-001, its lead investigational candidate for the treatment of hepatocellular carcinoma (HCC).</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Rznomics+Announces+U.S.+FDA+Regenerative+Medicine+Advanced+Therapy+Designation+Granted+to+%27RZ-001%27+for+Hepatocellular+Carcinoma/26456374.html Fri, 08 May 2026 04:17:00 -0400 476830 A.06822034 A.35552990 O.00074346 O.20026344 http://www.streetinsider.com/PRNewswire/Rznomics+Announces+U.S.+FDA+Regenerative+Medicine+Advanced+Therapy+Designation+Granted+to+%27RZ-001%27+for+Hepatocellular+Carcinoma/26456374.html <div class="xn-content"> <p><i>RMAT</i> <i>designation</i> <i>based on promising</i> <i>Phase</i> <i>1b/2a</i> <i>clinical data, including</i> <i>safety profile and preliminary response rates,</i> <i>with trans-splicing ribozyme-based RNA editing</i> <i>platform</i></p><p><span class="legendSpanClass"><location value="LU/kr..seoul" idsrc="xmltag.org" >SEOUL, South Korea</location></span>, <span class="legendSpanClass"><chron>May 8, 2026</chron></span> /PRNewswire/ -- Rznomics a biopharmaceutical company specializing in RNA-based gene therapeutics, announced today that the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food and Drug Administration</span> (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) Designation to RZ-001, its lead investigational candidate for the treatment of hepatocellular carcinoma (HCC).</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/PRNewswire/Rznomics+Announces+U.S.+FDA+Regenerative+Medicine+Advanced+Therapy+Designation+Granted+to+%27RZ-001%27+for+Hepatocellular+Carcinoma/26456374.html Fri, 08 May 2026 04:17:00 -0400 476830 A.06822034 A.35552990 O.00074346 O.20026344 http://www.streetinsider.com/Press+Releases/Rznomics+Announces+U.S.+FDA+Regenerative+Medicine+Advanced+Therapy+Designation+Granted+to+%27RZ-001%27+for+Hepatocellular+Carcinoma/26456374.html <div class="xn-content"> <p><i>RMAT</i> <i>designation</i> <i>based on promising</i> <i>Phase</i> <i>1b/2a</i> <i>clinical data, including</i> <i>safety profile and preliminary response rates,</i> <i>with trans-splicing ribozyme-based RNA editing</i> <i>platform</i></p><p><span class="legendSpanClass"><location value="LU/kr..seoul" idsrc="xmltag.org" >SEOUL, South Korea</location></span>, <span class="legendSpanClass"><chron>May 8, 2026</chron></span> /PRNewswire/ -- Rznomics a biopharmaceutical company specializing in RNA-based gene therapeutics, announced today that the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food and Drug Administration</span> (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) Designation to RZ-001, its lead investigational candidate for the treatment of hepatocellular carcinoma (HCC).</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Rznomics+Announces+U.S.+FDA+Regenerative+Medicine+Advanced+Therapy+Designation+Granted+to+%27RZ-001%27+for+Hepatocellular+Carcinoma/26456374.html Fri, 08 May 2026 04:17:00 -0400 476830 A.06822034 A.35552990 O.00074346 O.20026344 http://www.streetinsider.com/PRNewswire/Rznomics+Announces+U.S.+FDA+Regenerative+Medicine+Advanced+Therapy+Designation+Granted+to+%27RZ-001%27+for+Hepatocellular+Carcinoma/26456374.html <div class="xn-content"> <p><i>RMAT</i> <i>designation</i> <i>based on promising</i> <i>Phase</i> <i>1b/2a</i> <i>clinical data, including</i> <i>safety profile and preliminary response rates,</i> <i>with trans-splicing ribozyme-based RNA editing</i> <i>platform</i></p><p><span class="legendSpanClass"><location value="LU/kr..seoul" idsrc="xmltag.org" >SEOUL, South Korea</location></span>, <span class="legendSpanClass"><chron>May 8, 2026</chron></span> /PRNewswire/ -- Rznomics a biopharmaceutical company specializing in RNA-based gene therapeutics, announced today that the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food and Drug Administration</span> (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) Designation to RZ-001, its lead investigational candidate for the treatment of hepatocellular carcinoma (HCC).</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/PRNewswire/Rznomics+Announces+U.S.+FDA+Regenerative+Medicine+Advanced+Therapy+Designation+Granted+to+%27RZ-001%27+for+Hepatocellular+Carcinoma/26456374.html Fri, 08 May 2026 04:17:00 -0400 476830 A.06822034 A.35552990 O.00074346 O.20026344 http://www.streetinsider.com/Press+Releases/Rznomics+Announces+U.S.+FDA+Regenerative+Medicine+Advanced+Therapy+Designation+Granted+to+%27RZ-001%27+for+Hepatocellular+Carcinoma/26456374.html <div class="xn-content"> <p><i>RMAT</i> <i>designation</i> <i>based on promising</i> <i>Phase</i> <i>1b/2a</i> <i>clinical data, including</i> <i>safety profile and preliminary response rates,</i> <i>with trans-splicing ribozyme-based RNA editing</i> <i>platform</i></p><p><span class="legendSpanClass"><location value="LU/kr..seoul" idsrc="xmltag.org" >SEOUL, South Korea</location></span>, <span class="legendSpanClass"><chron>May 8, 2026</chron></span> /PRNewswire/ -- Rznomics a biopharmaceutical company specializing in RNA-based gene therapeutics, announced today that the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food and Drug Administration</span> (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) Designation to RZ-001, its lead investigational candidate for the treatment of hepatocellular carcinoma (HCC).</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Rznomics+Announces+U.S.+FDA+Regenerative+Medicine+Advanced+Therapy+Designation+Granted+to+%27RZ-001%27+for+Hepatocellular+Carcinoma/26456374.html Fri, 08 May 2026 04:17:00 -0400 476830 A.06822034 A.35552990 O.00074346 O.20026344 http://www.streetinsider.com/PRNewswire/Rznomics+Announces+U.S.+FDA+Regenerative+Medicine+Advanced+Therapy+Designation+Granted+to+%27RZ-001%27+for+Hepatocellular+Carcinoma/26456374.html <div class="xn-content"> <p><i>RMAT</i> <i>designation</i> <i>based on promising</i> <i>Phase</i> <i>1b/2a</i> <i>clinical data, including</i> <i>safety profile and preliminary response rates,</i> <i>with trans-splicing ribozyme-based RNA editing</i> <i>platform</i></p><p><span class="legendSpanClass"><location value="LU/kr..seoul" idsrc="xmltag.org" >SEOUL, South Korea</location></span>, <span class="legendSpanClass"><chron>May 8, 2026</chron></span> /PRNewswire/ -- Rznomics a biopharmaceutical company specializing in RNA-based gene therapeutics, announced today that the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food and Drug Administration</span> (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) Designation to RZ-001, its lead investigational candidate for the treatment of hepatocellular carcinoma (HCC).</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/PRNewswire/Rznomics+Announces+U.S.+FDA+Regenerative+Medicine+Advanced+Therapy+Designation+Granted+to+%27RZ-001%27+for+Hepatocellular+Carcinoma/26456374.html Fri, 08 May 2026 04:17:00 -0400 476830 A.06822034 A.35552990 O.00074346 O.20026344 http://www.streetinsider.com/Press+Releases/Rznomics+Announces+U.S.+FDA+Regenerative+Medicine+Advanced+Therapy+Designation+Granted+to+%27RZ-001%27+for+Hepatocellular+Carcinoma/26456374.html <div class="xn-content"> <p><i>RMAT</i> <i>designation</i> <i>based on promising</i> <i>Phase</i> <i>1b/2a</i> <i>clinical data, including</i> <i>safety profile and preliminary response rates,</i> <i>with trans-splicing ribozyme-based RNA editing</i> <i>platform</i></p><p><span class="legendSpanClass"><location value="LU/kr..seoul" idsrc="xmltag.org" >SEOUL, South Korea</location></span>, <span class="legendSpanClass"><chron>May 8, 2026</chron></span> /PRNewswire/ -- Rznomics a biopharmaceutical company specializing in RNA-based gene therapeutics, announced today that the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food and Drug Administration</span> (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) Designation to RZ-001, its lead investigational candidate for the treatment of hepatocellular carcinoma (HCC).</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Rznomics+Announces+U.S.+FDA+Regenerative+Medicine+Advanced+Therapy+Designation+Granted+to+%27RZ-001%27+for+Hepatocellular+Carcinoma/26456374.html Fri, 08 May 2026 04:17:00 -0400 476830 A.06822034 A.35552990 O.00074346 O.20026344 http://www.streetinsider.com/PRNewswire/Rznomics+Announces+U.S.+FDA+Regenerative+Medicine+Advanced+Therapy+Designation+Granted+to+%27RZ-001%27+for+Hepatocellular+Carcinoma/26456374.html <div class="xn-content"> <p><i>RMAT</i> <i>designation</i> <i>based on promising</i> <i>Phase</i> <i>1b/2a</i> <i>clinical data, including</i> <i>safety profile and preliminary response rates,</i> <i>with trans-splicing ribozyme-based RNA editing</i> <i>platform</i></p><p><span class="legendSpanClass"><location value="LU/kr..seoul" idsrc="xmltag.org" >SEOUL, South Korea</location></span>, <span class="legendSpanClass"><chron>May 8, 2026</chron></span> /PRNewswire/ -- Rznomics a biopharmaceutical company specializing in RNA-based gene therapeutics, announced today that the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food and Drug Administration</span> (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) Designation to RZ-001, its lead investigational candidate for the treatment of hepatocellular carcinoma (HCC).</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/PRNewswire/Rznomics+Announces+U.S.+FDA+Regenerative+Medicine+Advanced+Therapy+Designation+Granted+to+%27RZ-001%27+for+Hepatocellular+Carcinoma/26456374.html Fri, 08 May 2026 04:17:00 -0400 476830 A.06822034 A.35552990 O.00074346 O.20026344 http://www.streetinsider.com/Press+Releases/Rznomics+Reports+Interim+Clinical+Data+for+RZ-001+in+Hepatocellular+Carcinoma+at+AACR+2026+Demonstrating+Encouraging+Efficacy+and+Favorable+Safety+Profile/26338490.html <div class="xn-content"> <p>– RECIST-based ORR of 38.5% (confirmed) and 46.2% (unconfirmed)</p><p>– mRECIST-based ORR of 61.5% with a complete response (CR) rate of 23%</p><p>– No Grade 3 or higher adverse events related to RZ-001 observed</p><p>– Highlights clinical potential of RNA trans-splicing ribozyme platform technology</p><p><span class="legendSpanClass"><location value="LU/kr..seoul" idsrc="xmltag.org" >SEOUL, South Korea</location></span>, <span class="legendSpanClass"><chron>April 20, 2026</chron></span> /PRNewswire/ -- Rznomics announced today that it presented interim clinical data from its ongoing study of RZ-001, an RNA editing-based investigational anticancer therapy, in patients with hepatocellular carcinoma (HCC) during an oral presentation at the AACR 2026 (<span>American Association for Cancer Research</span> Annual Meeting), held on <chron>April 19, 2026</chron>, http://www.streetinsider.com/Press+Releases/Rznomics+Reports+Interim+Clinical+Data+for+RZ-001+in+Hepatocellular+Carcinoma+at+AACR+2026+Demonstrating+Encouraging+Efficacy+and+Favorable+Safety+Profile/26338490.html Mon, 20 Apr 2026 22:10:00 -0400 476830 http://www.streetinsider.com/PRNewswire/Rznomics+Reports+Interim+Clinical+Data+for+RZ-001+in+Hepatocellular+Carcinoma+at+AACR+2026+Demonstrating+Encouraging+Efficacy+and+Favorable+Safety+Profile/26338490.html <div class="xn-content"> <p>– RECIST-based ORR of 38.5% (confirmed) and 46.2% (unconfirmed)</p><p>– mRECIST-based ORR of 61.5% with a complete response (CR) rate of 23%</p><p>– No Grade 3 or higher adverse events related to RZ-001 observed</p><p>– Highlights clinical potential of RNA trans-splicing ribozyme platform technology</p><p><span class="legendSpanClass"><location value="LU/kr..seoul" idsrc="xmltag.org" >SEOUL, South Korea</location></span>, <span class="legendSpanClass"><chron>April 20, 2026</chron></span> /PRNewswire/ -- Rznomics announced today that it presented interim clinical data from its ongoing study of RZ-001, an RNA editing-based investigational anticancer therapy, in patients with hepatocellular carcinoma (HCC) during an oral presentation at the AACR 2026 (<span>American Association for Cancer Research</span> Annual Meeting), held on <chron>April 19, 2026</chron>, http://www.streetinsider.com/PRNewswire/Rznomics+Reports+Interim+Clinical+Data+for+RZ-001+in+Hepatocellular+Carcinoma+at+AACR+2026+Demonstrating+Encouraging+Efficacy+and+Favorable+Safety+Profile/26338490.html Mon, 20 Apr 2026 22:10:00 -0400 476830